3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
5
Leukemia, Hairy Cell
3
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Carcinoma in Situ
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Vomiting
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Nausea and Vomiting
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
NSCLC
1
Myelodysplastic Syndromes
1
Mastocytosis, Systemic
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
pembrolizumab
244
Carboplatin
214
Pemetrexed
180
Cisplatin
134
Paclitaxel
115
Nivolumab
102
Docetaxel
88
osimertinib
85
durvalumab
79
Specimen Handling
56
atezolizumab
55
Gemcitabine
53
Drug Therapy
53
Magnetic Resonance Spectroscopy
50
Radiosurgery
49
Radiotherapy
48
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
35
tislelizumab
31
Cetuximab
30
amivantamab
23
Taxes
22
Blood Specimen Collection
21
Platinum Compounds
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Diphenhydramine
×
1 year
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts